S&P 500 Rises 23% Since Trump's Inauguration Amid Growth Stocks Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: NASDAQ.COM
- Market Growth Trend: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor interest in high-growth sectors, particularly in innovative areas like artificial intelligence and quantum computing, which have driven overall market gains.
- Pharmaceutical Market Leader: Eli Lilly is leading the obesity drug market, with its products Mounjaro and Zepbound experiencing revenue growth in double and triple digits, and the recent launch of the oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson reported nearly 10% sales growth in its innovative medicines and medtech sectors, with total sales exceeding $24 billion in the latest quarter, indicating robust growth potential in the healthcare market.
- Future Growth Expectations: Johnson & Johnson aims to achieve $100 billion in annual revenue by 2023 and anticipates double-digit growth by the end of the decade, suggesting that demand for its medical products will remain strong even amid economic fluctuations, positioning the stock for continued appreciation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1160.950
Low
950.00
Averages
1192
High
1500
Current: 1160.950
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Electronics Mart Plans Diversification Amid AI Job Loss Concerns
- Revenue Diversification: Electronics Mart India derives about 60% of its revenue from Hyderabad, and as concerns about AI-triggered job losses grow, executives indicate a need to diversify to mitigate dependence on a single sector and ensure business stability.
- Expansion Plans: The company plans to invest approximately $12.69 million (about 1.2 billion rupees) to open 20 new stores in the current financial year, enhancing its market presence in regions including Kolkata and New Delhi.
- Market Competition Analysis: Compared to Mukesh Ambani's Reliance Digital and Tata Group's Croma, which have 695 and 540 stores respectively, Electronics Mart's 220 stores indicate a relatively smaller footprint, highlighting the competitive intensity in the retail sector.
- Future Growth Expectations: The company anticipates a revenue increase of about 15% this year, driven largely by strong demand for air conditioners during the hot summer, indicating that product demand remains robust amid changing climate conditions.
See More
Eli Lilly: A Leader in the GLP-1 Market
- GLP-1 Market Leadership: Eli Lilly has quickly overtaken Novo Nordisk in the GLP-1 weight-loss drug market, with Mounjaro's sales soaring 99% and Zepbound's by 175% in 2025, demonstrating strong market demand and the company's leadership position in this sector.
- Ongoing Innovation: Eli Lilly has introduced an oral version of its GLP-1 drug, which, while facing competition from Novo Nordisk's more effective pill, avoids dietary restrictions, potentially creating a competitive edge and broadening market share.
- Strategic Acquisition Moves: With nearly two-thirds of sales coming from Mounjaro and Zepbound, Eli Lilly's management recognizes the imbalance in its product portfolio and is actively acquiring to build an infectious disease business, ensuring diverse revenue streams for the future.
- Future Growth Potential: Despite Eli Lilly's high P/E ratio, its success in the GLP-1 space, continuous innovation, and strategic acquisitions leveraging GLP-1 profits make it an attractive option for growth-oriented investors.
See More
Reasons Investors Should Consider Eli Lilly Stock
- GLP-1 Market Leader: Eli Lilly has quickly overtaken Novo Nordisk in the GLP-1 weight-loss drug market, with Mounjaro's sales growing by 99% and Zepbound's by 175% in 2025, showcasing its strong market competitiveness and future growth potential.
- Continuous Innovation: Eli Lilly has introduced an oral version of its GLP-1 drugs; while Novo Nordisk's version is more effective, Eli Lilly's avoids dietary restrictions, potentially creating a complementary market presence and expanding its market share.
- Strategic Acquisition Moves: With nearly two-thirds of its sales coming from GLP-1 drugs, Eli Lilly's management is balancing its product portfolio through acquisitions of new drug candidates, ensuring sustained revenue and profitability post-patent expiration.
- Future Growth Potential: Despite a high P/E ratio, Eli Lilly's success in the GLP-1 space, ongoing innovation, and prudent acquisition strategy position it strongly for future drug development, making it attractive to growth-oriented investors.
See More
Eli Lilly Reports Positive Phase 3 Results for Jaypirca in CLL Treatment
- Clinical Trial Success: Eli Lilly's BRUIN CLL-322 trial demonstrated that the combination of Jaypirca with venetoclax and rituximab reduced the risk of disease progression or death by 45% in chronic lymphocytic leukemia patients, marking a significant improvement in treatment efficacy.
- Survival Rate Assessment: While overall survival (OS) as a key secondary endpoint is not yet mature, final testing for OS superiority is planned, indicating the potential value of the drug in chronic lymphocytic leukemia treatment.
- Treatment Safety: The overall safety profile of the combination therapy was consistent with the known safety profiles of each drug, and little additive toxicity was observed with the addition of Jaypirca, providing a solid safety foundation for clinical application.
- Industry Impact: BRUIN CLL-322 is the first Phase 3 study to show superiority over a venetoclax-containing control arm in chronic lymphocytic leukemia, reflecting current treatment patterns and emphasizing the potential of Jaypirca in improving treatment outcomes.
See More
BRUIN CLL-322 Study Shows Jaypirca Significantly Improves Outcomes in CLL Patients
- Clinical Trial Results: The BRUIN CLL-322 study demonstrated that the addition of Jaypirca to a regimen of venetoclax and rituximab reduced the risk of disease progression or death by 45% in chronic lymphocytic leukemia (CLL) patients, providing a more effective treatment option.
- Patient Recruitment: The study enrolled 639 patients with relapsed or refractory CLL, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the clinical applicability of the results in the current treatment landscape.
- Efficacy Assessment: At a median follow-up of 27.3 months, the primary endpoint of progression-free survival (PFS) was not reached in the Pirtobrutinib combination group, while the median PFS for the venetoclax and rituximab group was 39.7 months, highlighting the significant advantage of the combination therapy.
- Safety Analysis: The safety profile of BRUIN CLL-322 indicated that the addition of Pirtobrutinib did not significantly increase the incidence of adverse events, and treatment-related discontinuation rates were similar between the two groups, demonstrating good tolerability.
See More
BRUIN CLL-322 Study Shows Significant Superiority in CLL Treatment
- Clinical Trial Success: The BRUIN CLL-322 study demonstrates that the combination of Jaypirca (pirtobrutinib) with venetoclax and rituximab reduces the risk of disease progression or death by 45% (HR=0.55) compared to venetoclax and rituximab alone, providing a new treatment option for chronic lymphocytic leukemia (CLL) patients.
- Patient Recruitment: The study enrolled 639 patients with relapsed or refractory CLL, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the applicability of the results in the modern CLL treatment landscape and potentially establishing a new standard for second-line therapy.
- Efficacy Assessment: At a median follow-up of 27.3 months, the progression-free survival (PFS) in the PVR arm was not reached, while the VR arm reported 39.7 months, indicating significant efficacy of Jaypirca, particularly in high-risk patients who showed improved PFS.
- Safety Analysis: The safety profile of BRUIN CLL-322 was consistent with known safety profiles, with similar rates of Grade ≥3 adverse events between the PVR and VR groups (78.8% vs. 73.0%), demonstrating the good tolerability of Jaypirca and supporting its use in CLL treatment.
See More
Electronics Mart Plans Diversification Amid AI Job Loss Concerns
- Revenue Diversification: Electronics Mart India derives about 60% of its revenue from Hyderabad, and as concerns about AI-triggered job losses grow, executives indicate a need to diversify to mitigate dependence on a single sector and ensure business stability.
- Expansion Plans: The company plans to invest approximately $12.69 million (about 1.2 billion rupees) to open 20 new stores in the current financial year, enhancing its market presence in regions including Kolkata and New Delhi.
- Market Competition Analysis: Compared to Mukesh Ambani's Reliance Digital and Tata Group's Croma, which have 695 and 540 stores respectively, Electronics Mart's 220 stores indicate a relatively smaller footprint, highlighting the competitive intensity in the retail sector.
- Future Growth Expectations: The company anticipates a revenue increase of about 15% this year, driven largely by strong demand for air conditioners during the hot summer, indicating that product demand remains robust amid changing climate conditions.
See More
Eli Lilly: A Leader in the GLP-1 Market
- GLP-1 Market Leadership: Eli Lilly has quickly overtaken Novo Nordisk in the GLP-1 weight-loss drug market, with Mounjaro's sales soaring 99% and Zepbound's by 175% in 2025, demonstrating strong market demand and the company's leadership position in this sector.
- Ongoing Innovation: Eli Lilly has introduced an oral version of its GLP-1 drug, which, while facing competition from Novo Nordisk's more effective pill, avoids dietary restrictions, potentially creating a competitive edge and broadening market share.
- Strategic Acquisition Moves: With nearly two-thirds of sales coming from Mounjaro and Zepbound, Eli Lilly's management recognizes the imbalance in its product portfolio and is actively acquiring to build an infectious disease business, ensuring diverse revenue streams for the future.
- Future Growth Potential: Despite Eli Lilly's high P/E ratio, its success in the GLP-1 space, continuous innovation, and strategic acquisitions leveraging GLP-1 profits make it an attractive option for growth-oriented investors.
See More
Reasons Investors Should Consider Eli Lilly Stock
- GLP-1 Market Leader: Eli Lilly has quickly overtaken Novo Nordisk in the GLP-1 weight-loss drug market, with Mounjaro's sales growing by 99% and Zepbound's by 175% in 2025, showcasing its strong market competitiveness and future growth potential.
- Continuous Innovation: Eli Lilly has introduced an oral version of its GLP-1 drugs; while Novo Nordisk's version is more effective, Eli Lilly's avoids dietary restrictions, potentially creating a complementary market presence and expanding its market share.
- Strategic Acquisition Moves: With nearly two-thirds of its sales coming from GLP-1 drugs, Eli Lilly's management is balancing its product portfolio through acquisitions of new drug candidates, ensuring sustained revenue and profitability post-patent expiration.
- Future Growth Potential: Despite a high P/E ratio, Eli Lilly's success in the GLP-1 space, ongoing innovation, and prudent acquisition strategy position it strongly for future drug development, making it attractive to growth-oriented investors.
See More
Eli Lilly Reports Positive Phase 3 Results for Jaypirca in CLL Treatment
- Clinical Trial Success: Eli Lilly's BRUIN CLL-322 trial demonstrated that the combination of Jaypirca with venetoclax and rituximab reduced the risk of disease progression or death by 45% in chronic lymphocytic leukemia patients, marking a significant improvement in treatment efficacy.
- Survival Rate Assessment: While overall survival (OS) as a key secondary endpoint is not yet mature, final testing for OS superiority is planned, indicating the potential value of the drug in chronic lymphocytic leukemia treatment.
- Treatment Safety: The overall safety profile of the combination therapy was consistent with the known safety profiles of each drug, and little additive toxicity was observed with the addition of Jaypirca, providing a solid safety foundation for clinical application.
- Industry Impact: BRUIN CLL-322 is the first Phase 3 study to show superiority over a venetoclax-containing control arm in chronic lymphocytic leukemia, reflecting current treatment patterns and emphasizing the potential of Jaypirca in improving treatment outcomes.
See More
BRUIN CLL-322 Study Shows Jaypirca Significantly Improves Outcomes in CLL Patients
- Clinical Trial Results: The BRUIN CLL-322 study demonstrated that the addition of Jaypirca to a regimen of venetoclax and rituximab reduced the risk of disease progression or death by 45% in chronic lymphocytic leukemia (CLL) patients, providing a more effective treatment option.
- Patient Recruitment: The study enrolled 639 patients with relapsed or refractory CLL, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the clinical applicability of the results in the current treatment landscape.
- Efficacy Assessment: At a median follow-up of 27.3 months, the primary endpoint of progression-free survival (PFS) was not reached in the Pirtobrutinib combination group, while the median PFS for the venetoclax and rituximab group was 39.7 months, highlighting the significant advantage of the combination therapy.
- Safety Analysis: The safety profile of BRUIN CLL-322 indicated that the addition of Pirtobrutinib did not significantly increase the incidence of adverse events, and treatment-related discontinuation rates were similar between the two groups, demonstrating good tolerability.
See More
BRUIN CLL-322 Study Shows Significant Superiority in CLL Treatment
- Clinical Trial Success: The BRUIN CLL-322 study demonstrates that the combination of Jaypirca (pirtobrutinib) with venetoclax and rituximab reduces the risk of disease progression or death by 45% (HR=0.55) compared to venetoclax and rituximab alone, providing a new treatment option for chronic lymphocytic leukemia (CLL) patients.
- Patient Recruitment: The study enrolled 639 patients with relapsed or refractory CLL, with 79.8% having prior exposure to covalent BTK inhibitors, ensuring the applicability of the results in the modern CLL treatment landscape and potentially establishing a new standard for second-line therapy.
- Efficacy Assessment: At a median follow-up of 27.3 months, the progression-free survival (PFS) in the PVR arm was not reached, while the VR arm reported 39.7 months, indicating significant efficacy of Jaypirca, particularly in high-risk patients who showed improved PFS.
- Safety Analysis: The safety profile of BRUIN CLL-322 was consistent with known safety profiles, with similar rates of Grade ≥3 adverse events between the PVR and VR groups (78.8% vs. 73.0%), demonstrating the good tolerability of Jaypirca and supporting its use in CLL treatment.
See More
